G
Gary Bridger
Researcher at Genzyme
Publications - 38
Citations - 3313
Gary Bridger is an academic researcher from Genzyme. The author has contributed to research in topics: Plerixafor & CXCR4. The author has an hindex of 23, co-authored 38 publications receiving 3153 citations. Previous affiliations of Gary Bridger include Rega Institute for Medical Research.
Papers
More filters
Journal ArticleDOI
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma
John F. DiPersio,Edward A. Stadtmauer,Auayporn Nademanee,Ivana N. Micallef,Patrick J. Stiff,Jonathan L. Kaufman,Richard T. Maziarz,Chitra Hosing,Stefan Fruehauf,Mitchell E. Horwitz,Dennis L. Cooper,Gary Bridger,Gary Calandra +12 more
TL;DR: Plerixafor and G- CSF were well tolerated, and significantly more patients collected the optimal CD34(+) cell/kg target for transplantation earlier compared with G-CSF alone.
Journal ArticleDOI
Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100
Bruno Nervi,Pablo Ramirez,Michael P. Rettig,Geoffrey L. Uy,Matthew Holt,Julie Ritchey,Julie L. Prior,David Piwnica-Worms,Gary Bridger,Timothy J. Ley,John F. DiPersio +10 more
TL;DR: A mouse model of acute promyelocytic leukemia and a small molecule competitive antagonist of CXCR4, AMD3100, are used to examine the interaction of mouse APL cells with the BM microenvironment to provide a proof-of-principle for directing therapy to the critical tethers that promote AML-niche interactions.
Journal ArticleDOI
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection
Craig W. Hendrix,Ann C. Collier,Michael M. Lederman,Dominique Schols,Richard B. Pollard,Stephen J. Brown,J. Brooks Jackson,Robert W. Coombs,Marshall J. Glesby,Charles Flexner,Gary Bridger,Karin Badel,Ronald Trevor Macfarland,Geoffrey W. Henson,Gary Calandra +14 more
TL;DR: Given these results, AMD3100 is not being further developed for ARV therapy, but development continues for stem cell mobilization.
Journal ArticleDOI
Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction.
Steven M. Devine,Ravi Vij,Michael P. Rettig,Laura Todt,Kiley McGlauchlen,Nicholas Fisher,Hollie Devine,Daniel C. Link,Gary Calandra,Gary Bridger,Peter Westervelt,John F. DiPersio +11 more
TL;DR: Direct antagonism of CXCR4 by AMD3100 may provide a more rapid and possibly less toxic and cumbersome alternative to traditional G-CSF-based mobilization in normal donors.
Journal ArticleDOI
AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data.
G. Calandra,John M. McCarty,Joseph McGuirk,Guido Tricot,S.-A. Crocker,Karin Badel,Grove B,Dye A,Gary Bridger +8 more
TL;DR: It is shown that AMD3100 plus G-CSF offers a new treatment to collect CD34+ cells for autologous transplant from poor mobilizers, with a high success rate.